SG Americas Securities LLC Has $241.18 Million Stock Position in Medtronic PLC $MDT

SG Americas Securities LLC raised its position in shares of Medtronic PLC (NYSE:MDT) by 2,297.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,510,712 shares of the medical technology company’s stock after buying an additional 2,406,000 shares during the period. SG Americas Securities LLC owned about 0.20% of Medtronic worth $241,179,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after acquiring an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC raised its position in shares of Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after acquiring an additional 381 shares during the last quarter. AlphaCore Capital LLC lifted its stake in Medtronic by 5.6% in the second quarter. AlphaCore Capital LLC now owns 6,165 shares of the medical technology company’s stock valued at $535,000 after buying an additional 326 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Medtronic by 1.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 8,160,266 shares of the medical technology company’s stock valued at $711,330,000 after acquiring an additional 118,314 shares during the period. Finally, Coldstream Capital Management Inc. raised its holdings in Medtronic by 4.1% in the second quarter. Coldstream Capital Management Inc. now owns 52,457 shares of the medical technology company’s stock worth $4,573,000 after purchasing an additional 2,070 shares during the period. 82.06% of the stock is owned by institutional investors.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Trading Up 1.3%

Shares of MDT stock opened at $87.24 on Tuesday. The stock has a 50 day simple moving average of $96.63 and a 200 day simple moving average of $96.69. The stock has a market cap of $112.01 billion, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 2.21 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is presently 79.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on MDT shares. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a research report on Tuesday, January 6th. Citigroup started coverage on shares of Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Truist Financial cut their target price on shares of Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. Finally, UBS Group reaffirmed a “neutral” rating and set a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.74.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).